The Gynecologic-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center (DFBWCC) provides multidisciplinary diagnostic care and treatment for patients with gynecologic cancers including ovarian, endometrial, cervical, vulvar and vaginal cancers and gestational trophoblastic disease. The Gynecologic-Oncology Program at DF/BWCC unites specialists from one of the world’s leading cancer institutes with experts from our top-ranked hospital.
Our Gynecologic-Oncology Program team includes physician leaders in gynecology, surgical oncology, medical oncology, pathology and radiation oncology, working alongside nurses, geneticists, infertility specialists, sexual health specialists, pharmacists, social workers, nurses, palliative care specialists and researchers. The experts on our team continually collaborate with each other and with patients and families to ensure the best possible outcomes – medically, emotionally and spiritually.
We offer the most advanced approaches – from pathologists who are exclusively dedicated to diagnosing gynecologic cancer to surgical oncologists who are leading experts in minimally invasive surgical procedures, including robotic-assisted surgery. DF/BWCC was the first center in New England to treat endometrial cancer using robotic-assisted surgery.
The Enhanced Recovery After Surgery (ERAS) refers to a philosophy of surgical care that minimizes the physical stress of surgery on your body and returns you to normal function as quickly as possible. The key principles of ERAS are 1) avoidance of prolonged fasting; 2) early ambulation; 3) minimization of opioids, and 4) good prophylactic measures. We want you to return to doing the things you love safely, quickly, and more comfortably. Learn more about the ERAS program.
Patients have access to a wide range of therapies, including proven chemotherapy treatments and targeted radiation options as well as complimentary therapies that relieve symptoms and side-effects. The majority of women with ovarian cancer present with advanced stage disease that has already spread within the abdominal cavity. The combination of intravenous chemotherapy and surgery is the best treatment approach for many women. However, recent studies have shown that a significant improvement in survival can be seen for select patients receiving hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of surgery. HIPEC delivers chemotherapy directly to cancer cells in the abdomen, so it is well-suited to the treatment of ovarian cancer. During HIPEC, chemotherapy is briefly placed in the abdomen at the time of surgery. Heating the chemotherapy improves absorption of chemotherapy and directly destroys cancer cells. At the completion of the surgery, the chemotherapy is removed from the abdomen. Of equal importance, recent studies have also shown that adding HIPEC to a patient’s treatment doesn’t increase patient side-effects or complications. HIPEC is for select patients with advanced stage ovarian cancer and we encourage patients to discuss treatment options with their cancer team.